Introduction
============

The application of mass spectrometry (MS) to bacterial identification was firstly proposed by [@B3], based on the observation that different mass spectra were obtained from bacterial extracts of different species. However, the hard ionization allowed detecting only bacterial lipids, which limited the possibility to discriminate bacteria at species level. The analysis of high molecular mass biomolecules, such as polypeptides, became possible only in the second half of the 1980s, after the development of soft ionization techniques ([@B101]). [@B38] showed that specific spectral fingerprints could be obtained from whole bacterial cells by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS analysis, paving the way for microbial identification by MS. Subsequent developments have mainly focused on software and database improvements, making MALDI-TOF MS an increasingly robust and accurate tool for microbial identification ([@B52]).

Matrix-assisted laser desorption/ionization is a soft ionization technique allowing ionization and vaporization of intact, high molecular mass biomolecules. The analyzed spectrum is usually between 2 and 20 kDa, a molecular mass range dominated by ribosomal proteins ([@B86]). The suppression of ionization of high-mass/acidic/low abundant proteins in presence of low-mass/basic/abundant ones yields MALDI mass spectra containing signals in the 2--20 kDa range. Microbial identification is achieved by comparing the observed spectrum with those stored in a database. Using a MALDI Biotyper-based identification (Bruker Daltonics), a score value between 0 and 3 is calculated by the software on the basis of peak similarities between the observed spectrum and stored reference spectra; score values of ≥2.00 indicate high confidence species ID, score values ≥1.70 and \<2.00 are reported as low confidence ID, and scores \<1.7 are considered as unreliable (no ID). However, the results of several studies suggest that lower score cut-off values might be applied for identification of many bacterial species without compromising accuracy ([@B84]; [@B100]; [@B6]), and it has been suggested that species-specific score cut-off values might be defined and applied in a species-specific manner ([@B84]) in order to optimize MALDI-TOF MS identification.

With the Vitek MS system (bioMérieux, Marcy-l'Étoile, France), the acquired mass spectrum is divided into 1,300 bins, and a score is generated and converted to a probability percentage and confidence value by comparing the peak patterns with those in the database; threshold values for reliable species identification are fixed in the binning algorithm^[1](#fn01){ref-type="fn"}^.

Identification of Bacteria
==========================

Conventional microbiological methods for bacterial identification involve culture, microscopic examination and biochemical testing. These procedures can be accurate and reliable, at least for most of classical microbial pathogens, but they are also time consuming, laborious, and require specifically trained personnel for correct interpretation of results. Conversely, MS is rapid, reliable and easy to perform, it is reproducible ([@B107]), and has the potential to replace or complement conventional biochemical methods for identification of bacteria, especially for emerging opportunistic pathogens that may be difficult to identify on the sole basis of biochemical tests. A small amount of bacterial biomass is required, and sample preparation for analysis is, in most cases, rapid and easy to perform. The spectral fingerprint obtained is compared with a database of reference spectra and a result is generated on the basis of peak similarities ([@B9]).

Matrix-assisted laser desorption/ionization-time of flight MS has been shown able to achieve correct identification rates comparable to or higher than those of the BD Phoenix (Becton Dickinson) and Vitek 2 (bioMérieux) automated ID systems, besides shortening identification time from 24 to 48 h to just a few minutes ([@B28]; [@B36]). The Bruker Biotyper (Bruker Daltonics) and Vitek MS (bioMérieux) are two of the most widely used MALDI-TOF MS systems for bacterial identification in diagnostic microbiology laboratories. In the overall, the two systems have shown similar performances ([@B16]; [@B22]; [@B67]; [@B68]; [@B1]; [@B50]; [@B69]; [@B58]). In a first evaluation of the accuracy of the Bruker system for routine identification of bacteria, the system correctly identified 95.4% of the 1660 bacterial isolates tested, 84.1% at species level and 11.3% at genus level ([@B94]). Lack of identification and misidentification were mainly due to insufficient database entries for some bacterial species but these limitations could be overcome by the addition of spectra of successfully identified clinical isolates into commercial databases ([@B94]; [@B32]; [@B74]; [@B12]; [@B65]).

In the overall, the quality of the reference database is a fundamental prerequisite for correct identification of clinical isolates, and highly reliable ID results can be achieved by database incorporation of spectra of ascertained microbial species, including rare bacterial species ([@B93]). Improvement of database entries with multiple spectra of well-characterized species has been shown to yield high identification rates for *Clostridium* spp., *Mycobacterium* spp. ([@B81]; [@B29]) and *Helicobacter pylori* ([@B108]), amongst others. However, for microorganisms with complex cell wall composition such as *Mycobacterium* spp., the accuracy of identification is often sub-optimal ([@B11]), and specific pretreatment may be required for protein extraction before MALDI-TOF MS analysis can be effectively performed ([@B78]; [@B71]). Moreover, identification of some bacterial species may be still problematic, especially for Gram-positive bacteria such as *Streptococcus pneumoniae* and members of the *Streptococcus oralis/mitis* group ([@B65]; [@B95]), and *Listeria* spp. ([@B31]) but also for some Gram-negative bacteria such as *Shigella* spp., having low rate of differences in their ribosomal protein sequence with *Escherichia coli* ([@B51]), some *Enterobacter* spp. ([@B30]), and some strains of *Stenotrophomonas maltophilia* ([@B39]); in addition, MALDI-TOF MS identification of anaerobes at species level may be problematic ([@B85]).

Microbial identification in polymicrobial samples by MALDI-TOF MS is also challenging, though some studies have shown that can be feasible ([@B64]; [@B87]). In many cases, the prevailing microorganism among those grown in blood culture (BC) can be correctly identified ([@B35]).

On the other hand, in a few cases, MALDI-TOF MS can provide an excellent means to identify bacterial species that biochemically-based microbiology has difficulty to distinguish, as in the case of *Haemophilus influenzae* and *Haemophilus haemolyticus* ([@B110]).

Matrix-assisted laser desorption/ionization MS has also been evaluated for direct identification of microorganisms in complex biological fluids such as urine and BCs. Regarding urine, implementation of MALDI-TOF MS together with total laboratory automation significantly reduced turnaround time to identification, AST report, and preliminary negative results ([@B102]). Microbial identification directly from positive BCs is described below.

Of interest, a comprehensive analysis of the *Treponema pallidum* proteome has been recently carried out ([@B76]), laying the foundations for a possible, future MALDI-TOF MS-based identification of this important bacterial pathogen.

Rapid Identification of Bacteria From Positive Blood Cultures
=============================================================

The short time and tiny amount of microbial biomass required for analysis make MALDI-TOF MS one of the most promising techniques for the identification of microbial pathogens directly from positive BCs ([@B54]; [@B72]; [@B55]; [@B18]; [@B47]; [@B63]; [@B6]). To this purpose, separation of microorganisms from blood cells is a critical step for successful identification of bacteria in monomicrobial BCs by MALDI-TOF MS ([@B17]). Several sample preparation protocols have been proposed to separate bacteria from host cells and proteins through cell lysis and/or differential centrifugation steps ([@B17]; [@B99]; [@B91]), and differences in sample processing methods may account, at least in part, for the observed variability in correct identification rates ([@B60]). An alternative to cell lysis and/or differential centrifugations is purification of bacteria from BC using serum separator tubes (SSTs), which is simple, rapid and yields a relatively high recovery of bacteria ([@B61]; [@B6]).

It should be mentioned that, due to the additional processing time, most microbiological laboratories use these methods in batches, thus reducing the time-saving achievable by a faster method. A simple, rapid and reliable method that does not necessarily require to work in batches has been proposed by [@B6].

Several studies indicate that integrating rapid MALDI-TOF MS identification with antimicrobial stewardship intervention for streamlining empirical antimicrobial therapy in patients with bloodstream infections can improve patient outcomes significantly, compared to reporting ID results alone ([@B43]; [@B73]; [@B79]; [@B59]). In addition, rapid MALDI-TOF MS identification results can be used optimally in combination with rapid molecular and/or phenotypic methods for the detection of antimicrobial resistance ([@B62]; [@B63]; [@B5]).

Adopting lower score cut-offs than those indicated by the systems' manufacturers, preferably complemented by additional validation criteria, has been often proposed for microorganisms recovered from positive BCs ([@B45]; [@B6]), due to the high background in these samples.

Assessment of Antimicrobial Resistance and Strain Typing
========================================================

Matrix-assisted laser desorption/ionization MS can be useful for the detection of bacterial resistance to β-lactam antibiotics mediated by β-lactamases ([@B10]; [@B42], [@B41]; [@B40]; [@B98]). The hydrolysis of the β-lactam ring can be detected by MS as the disappearance of the original mass peak of the antibiotic and appearance of the corresponding hydrolytic products ([@B49]).

Several studies have been undertaken aimed at identifying proteomic differences between methicillin-resistant and methicillin-sensitive *Staphylococcus aureus* and/or between vancomycin-resistant and vancomycin-sensitive *Enterococcus faecium*, and discriminating methicillin-resistant *S. aureus* lineages using MALDI-TOF MS ([@B27]; [@B90]; [@B34]; [@B48]; [@B97]; [@B106]). However, a study aimed at identifying lineage-specific biomarker peaks revealed only limited possibilities to differentiate *S. aureus* as well as *E. faecium* below the species level ([@B56]), suggesting that phenotypic differences may not always be detectable in a MALDI TOF mass spectrum.

In an attempt to overcome these difficulties, an indirect method has been established to detect methicillin resistance in a particular subset of *S. aureus* isolates. This method is based on the evidence that some MRSA strains produce a phenol-soluble protein toxin, called PSM-mec, belonging to the modulin family ([@B14]). The presence of PSM-mec could be detected by MALDI-TOF MS as a 2415 ± 2 m/z peak ([@B83]).

The *psm-mec* gene, coding for the PSM-mec peptide, is present in the class A mec gene complex, which is carried by staphylococcal cassette chromosome mec (SCCmec) types II, III, and VIII ([@B14]), and may be present in up to half of MRSA isolates ([@B23]; [@B83]). PSM-mec does not cause methicillin resistance, and its biological function is still under investigation. Absence of this toxin does not imply methicillin susceptibility and, therefore, additional methods are still required to confirm MSSA isolates. However, expression of PMS-mec is closely correlated with methicillin resistance and, therefore, if PSM-mec is detected in a *S. aureus* clinical isolate, then resistance to methicillin can be inferred.

The specificity of predicting mecA carriage in *S. aureus* by detection of the 2415 ± 2 m/z peak is very high and can reach 100% ([@B83]). In 2016, Bruker has released a software that automates this analysis, called "MBT subtyping module," which is specifically designed to detect the PSM-mec peptide in *S. aureus*, thus obtaining indirect detection of methicillin resistance.

Another application of MALDI-TOF MS has been described for the detection of antimicrobial resistance determinants based on the identification of plasmids bearing *bla~KPC~* carbapenemase genes ([@B57]), conferring resistance to carbapenems. Plasmid identification by MALDI-TOF MS can be accomplished in a few minutes and, ultimately, provides clinically useful information, given the widespread diffusion of this kind of antibiotic resistance.

A recent method proposed by [@B46] is based on the possibility to measure the metabolic inhibition, evaluated as decrease in protein synthesis induced after exposure of microorganisms to antimicrobial drugs. The assay is performed directly on the target plate used for MS analysis; it is rapid, yielding results within 5 h, and is not limited to a single class of antibiotics.

In the overall, the discriminatory power of MALDI-TOF MS in strain typing is presently still under investigation ([@B88]), and further studies will be needed to assess whether new methods for detection of antibiotic resistance by MALDI-TOF MS can be effectively applied as routine assays in clinical microbiology laboratories.

Identification of Fungal Pathogens and Antifungal Susceptibility Testing
========================================================================

The incidence of invasive fungal infections has steadily increased during the last decades ([@B8]; [@B21]; [@B77]), mainly due to the growing number of immunocompromised patients and, hence, the prolonged use of broad spectrum antibiotics. Besides the most commonly isolated species, such as *Candida* *albicans* and *Aspergillus* spp., a number of emerging fungal pathogens has been isolated with increased frequency, including *Candida glabrata* ([@B19]; [@B80]), *Trichosporon* spp. ([@B24]), and filamentous fungi such as *Scedosporium* spp., *Fusarium* spp., and *Mucorales* ([@B105]; [@B25]).

Matrix-assisted laser desorption/ionization MS fingerprint represents a robust tool for routine rapid identification of clinically relevant fungi ([@B66]; [@B13]; [@B82]; [@B4]; [@B15]; [@B7]; [@B26]; [@B103]). However, due to their thick cell wall, obtaining high-quality MALDI-TOF MS spectra of fungal pathogens is more challenging than for most bacterial species and requires optimization and standardization of culture media, growth conditions and extraction procedures. To obtain high quality MALDI-TOF mass spectra, fungal cells may need to be lysed in 70% formic acid and/or by mechanical disruption in a bead-beater ([@B2]; [@B37]; [@B13]).

Systemic infections due to *Candida* spp. are characterized by high mortality rates, especially when associated to septic shock and if an effective antifungal therapy is not timely administered ([@B53]). Since different *Candida* species are characterized by different susceptibility profiles to antifungal agents, a rapid species identification may have an impact on the patients' outcomes. Correct identification rates by MALDI-TOF MS directly on positive BC have been correlated with both the protocol used and BC fungal load ([@B33]; [@B109]; [@B96]; [@B75]).

A combined approach was applied to very short-term BCs by evaluating MALDI-TOF MS identification while using the same yeast cell pellets to inoculate Vitek 2 cards for antifungal susceptibility testing (AFST) ([@B45]). AFST results were obtained for 72.7% of positive BCs directly tested by Vitek 2 and essential agreement was 88.6%. However, for some of the isolates the test aborted, and performance for azole susceptibility testing was sub optimal ([@B45]). An alternative method is based on plating small BC aliquots, after lysis, onto solid media before BCs became positive, followed by MALDI-TOF MS analysis of yeast microcolonies ([@B44]). This method allowed identifying different *Candida* spp. in spiked blood samples; however, the applicability of this method in a routine laboratory workflow should be evaluated. A schematic representation of the different methods proposed for yeast identification in blood samples is reported in **Figure [1](#F1){ref-type="fig"}**.

![Schematic representation of the different procedures described for identification of yeasts in blood samples by MALDI-TOF MS.](fmicb-09-01097-g001){#F1}

Another interesting approach for a rapid diagnosis of candidaemia is based on detection of specific biomarkers in sera of patients with invasive candidiasis ([@B92]; [@B70]). In particular, by MALDI-TOF MS analysis, [@B92] identified a disaccharide corresponding to a specific peak of m/z 365 in sera of patients with candidaemia. Further studies will help to assess the clinical utility of this biomarker for an early diagnosis of candidaemia.

A promising method to detect specific resistance to antifungal agents is based on the comparison of MALDI-TOF MS spectra of a yeast isolate after incubation with high, intermediate or null antifungal concentrations ([@B104]; [@B89]). Using this approach, [@B89] evaluated the resistance to triazoles in *C. albicans, C. tropicalis*, and *C. glabrata*: essential agreement between MALDI-TOF MS and conventional AFST ranged between 54 and 97%, and the reproducibility of the MALDI-TOF MS assay between 54.3 and 82.9%, depending on the triazole drug and *Candida* species. However, the time saving using this method over the reference AFST method ([@B20]) was modest (overnight vs. 24 h). In a similar study, a 3-h incubation showed to be sufficient for detection of resistance to caspofungin (CSF) in *C. albicans* isolates ([@B104]). Further studies will show whether such a short-time incubation may be sufficient to yield accurate and reliable AFST results.

Concluding Remarks
==================

Matrix-assisted laser desorption/ionization MS has provided a new approach for rapid, reliable, and cost-effective microbial identification. Several studies have shown that the accuracy of MALDI-TOF MS in microbial identification is comparable or superior to automated systems based on biochemical and other phenotypic tests. Indeed, at present many laboratories rely on MALDI-TOF MS for routine identification of microbial pathogens, and can use automated ID systems to confirm uncertain (low-score) identifications, thus achieving correct ID rates very close to 100%, in the overall. Other applications of MALDI-TOF MS in diagnostic microbiology, such as direct sample analysis, prediction of antimicrobial resistance and strain typing, are being developed and evaluated, exploring the possibilities and limits of this technology.
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